Investor Relations

Stock price graph
DDXS [OT] : $0.52  - 0.03
Last Updated: 2:24 PM ET on Oct 1, 2014

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease.

The PLAC Test for Lp-PLA2, diaDexus' flagship product, addresses key unmet medical need, providing actionable information. The PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States.

diaDexus Corporate Fact Sheet - March 2014 PDF

PLAC Test Fact Sheet - January 2014 PDF

Lp-PLA2 Fact Sheet - January 2014 PDF

Heart Failure Fact Sheet - March 2014 PDF

View all »   RSSRecent Releases

Sep 22, 2014
diaDexus, Inc. Announces Appointment of Kenneth Fang, M.D., as Chief Medical Officer

Sep 9, 2014
diaDexus, Inc. Announces Resignation of Chief Financial Officer


©2014 diaDexus, Inc. | diaDexus and PLAC are U.S. Registered Trademarks of diaDexus, Inc.